---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-000168"
form_type: "8-K"
ticker: "SNOA"
cik: "0001367083"
company_name: "Sonoma Pharmaceuticals, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:52:43.160723+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Sonoma provides January 2024 investor presentation; no material new financial data

## Summary
- Presentation reiterates stabilized HOCl platform for dermatology, wound, eye, nasal, oral, animal health.
- Products sold in 55 countries directly or through distribution partners.
- Company actively seeking additional distribution partners to expand global reach.

## SEC filing metadata
- accession: 0001683168-24-000168
- form_type: 8-K
- ticker: SNOA
- cik: 0001367083
- company_name: Sonoma Pharmaceuticals, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367083/000168316824000168/0001683168-24-000168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367083/000168316824000168/sonoma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-000168
- JSON: https://secwatch.observer/filing/0001683168-24-000168.json
- Plain text: https://secwatch.observer/filing/0001683168-24-000168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.